Markets

CEO turned informant: How the FDA built a case against executives promising cheap medications

World desk, Times News (2026-11-18): The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record. Primary source: original at CNBC Top News (cnbc.com).

· CNBC Top News

CEO turned informant: How the FDA built a case against executives promising cheap medications

The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.

Read at source